CABA Stock Price Chart
CABA Earnings
Cabaletta Bio Inc
$3.83
30.27%
$0.89
At close: May 04, 16:00:00 GMT-4
$3.76
-1.79%
$-0.06
Post-market: May 04, 19:48:16 GMT-4
Back
Cabaletta Bio Inc (CABA) Earnings
Key Stats
Prev.Close
$2.94
Open
$3.18
Day's Range
$3.16 - $4.04
52 week range
$1.11 - $3.78
Volume
29.1M
Avg.Volume
2.6M
Dividend yield
--
EPS (TTM)
-2.28
Market Cap
$418.7M
What is CABA?
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania and currently employs 148 full-time employees. The company went IPO on 2019-10-25. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
